Movement Disorders Journal

Overview
Identity
View All

publication venue for

Diagnosing Parkinson’s disease by Combining Neuromelanin and Iron Image Features Using Automatic SN Subregions Detection Approach 2022
Imaging Proton Spin Density as a Means to Map Neuromelanin: A Novel Approach for Neuromelanin Sensitive MRI in Parkinson's Disease 2022
Microvascular Imaging of the Midbrain Using USPIO-Enhanced MRI 2022
Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 double-blind, placebo-controlled trial 2018
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from a Phase 3 double-blind, placebo-controlled trial 2018
Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease (PD) from OFF to fully ON: preliminary results from a phase iii study 2017
Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: results from the Phase 3 study dose-titration phase 2017
Motor dysfunctions in rats following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin 2017
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: preliminary results from a Phase III Study 2017
Study design of an efficacy and safety phase 3, randomized, double-blind, placebo-controlled trial of APL-130277 in the treatment of OFF episodes (CTH-300) 2017
Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 study dose-titration phase 2017
Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 study dose titration phase 2017
Study design of an efficacy and safety phase 3, randomized, double-blind, placebo-controlled trial of APL-130277 in the treatment of OFF episodes (CTH-300) 2017
APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa 2016
Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease from OFF to fully ON 2016
Minimum MDS-UPDRS part III change needed to convert a Parkinson's disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277) 2016
Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study 2016
Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson's disease 2016
Treatment of OFF episodes in Parkinson's disease: An evaluation of patient and caregiver insights 2016
Treatment of OFF episodes in Parkinson's disease: An evaluation of physician practices 2016
Efficacy of sublingual apomorphine (APL-130277) for the treatment of "off" episodes in patients with Parkinson's disease 2015
Pharmacokinetics, safety and tolerability of high-dose sub-lingually administered APL-130277 in healthy volunteers 2015
Pharmacokinetics, safety and tolerability of sub-lingually administered APL-130277 compared to subcutaneous apomorphine in healthy volunteers 2015
Safety of sublingual APL-130277 for the treatment of OFF episodes in patients with Parkinson's disease 2015
A pilot study evaluating the histamine H2 antagonist, famotidine, for levodopa-induced dyskinesia in Parkinson's disease 2014
Pure parkinsonism in chorea-acanthocytosis: Postmortem evidence for a striato-pallidal process without involvement of the substantia nigra pars compacta 2012
Somatosensory Processing in Parkinson's Disease 2010
A patient with Gaucher's disease successfully treated with pallidotomy, a 3-year follow up 2007
Clinical characterization of familial and sporadic Restless legs syndrome 2007
Tactile training with or without 1Hz rTMS to primary motor cortex: A case study in two patients with focal hand dystonia 2007
Total body lead burden and the risk of Parkinson's disease 2004
Small and Large Magnetic Resonance Imaging–Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. 37:1304-1309. 2022
Evidence for Non‐Mendelian Inheritance in Spastic Paraplegia 7. 36:1664-1675. 2021
Clustering of motor and nonmotor traits in leucine‐rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. 33:960-965. 2018
Heart rate variability in leucine‐rich repeat kinase 2‐associated Parkinson's disease. 32:610-614. 2017
Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. 31:1366-1372. 2016
Dysregulation of novel catecholamine‐regulated protein 40 (CRP40) in Parkinson's disease patients. 28:1460-1461. 2013
Rational therapy: If only it were so. 26:1948-1948. 2011
Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype. 26:753-755. 2011
Definition and classification of hyperkinetic movements in childhood. 25:1538-1549. 2010
Heterogeneity of presentation and outcome in the Irish rapid‐onset dystonia–Parkinsonism kindred. 22:1325-1327. 2007
Bimanual coordination deficits with Parkinson's disease: The influence of movement speed and external cueing. 17:30-30. 2002
Bimanual coordination deficits with Parkinson's disease: The influence of movement speed and external cueing. 17:30-37. 2002
Reply. 15:180-181. 2000
Catatonia: Re-awakening to a forgotten disorder. 14:395-397. 1999
Case 1, 1991: A severe and fatal systemic illness first presenting with a movement disorder. 6:362-370. 1991

has subject area

1103 Clinical Sciences (FoR)
1106 Human Movement and Sports Sciences (FoR)
1109 Neurosciences (FoR)
Neurology & Neurosurgery (Science Metrix)